• January 2010

    Opening Date

  • April 2011

    Beginning of Ultrasound Treatments

  • February 2013

    Beginning of Commercial Activity

  • We offer to patients suffering from chronic and therapy-resistant functional brain disorders, a sparing concept centered on millimeter-large and abnormally functioning brain targets, allowing bilateral treatments and absence of neurological deficits, and the exclusive use of the new focused ultrasound technology, which reduces most significantly the treatment risks and optimizes targeting precision.

  • 20+ years

    of Academic Research

  • 1000+

    Stereotactic Treatments

  • <1 mm

    Targeting Accuracy

General Treatment facts

  • 193

    FUS Interventions

  • 290

    Targets Sonicated

  • 0

    Bleedings

  • 2

    Transient minor neurological complications

Targeting Accuracies

Difference between the atlas target coordinates and the lesion coordinates, as measured on 2 days post-operative MRI scans:

  • 0.32

    mm in Medio-Lateral direction

  • 0.31

    mm in Antero-Posterior direction

  • 0.42

    mm in Dorso-Ventral direction

  • 0.72

    mm as three-dimensional vector